← All trials
NCT06202625
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2024
- Primary completion
- Oct 30, 2024
- Completion date
- Oct 30, 2025
- First posted
- Jan 11, 2024
- Last posted
- Oct 1, 2024
- Enrollment
- 142
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Peking UniversityLead sponsor
- Peking UniversitySponsor investigator
- Central South UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Peking UniversityOfficial
- Shanxi Bethune HospitalCollaborator
- Harbin Medical UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- People's Liberation Army of ChinaCollaborator
- Nanchang UniversityCollaborator
- Xinjiang Medical UniversityCollaborator
- Sichuan UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.